Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Other Non Operating Income: 2009-2024

Historic Other Non Operating Income for OptimizeRx (OPRX) over the last 9 years, with FY2024 value amounting to $152000.0.

  • OptimizeRx's Other Non Operating Income rose 6315.79% to $62000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $175000.0, marking a year-over-year decrease of 691.49%. This contributed to the annual value of $152000.0 for FY2024, which is 6960.0% down from last year.
  • Latest data reveals that OptimizeRx reported Other Non Operating Income of $152000.0 as of FY2024, which was down 6960.0% from $500000.0 recorded in FY2023.
  • OptimizeRx's 5-year Other Non Operating Income high stood at $852298.0 for FY2022, and its period low was -$71808.0 during FY2020.
  • In the last 5 years, OptimizeRx's Other Non Operating Income had a median value of $152000.0 in 2024 and averaged $289893.8.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 491971.85% in 2022, then crashed by 6960.0% in 2024.
  • Annual analysis of 5 years shows OptimizeRx's Other Non Operating Income stood at -$71808.0 in 2020, then skyrocketed by 123.64% to $16979.0 in 2021, then skyrocketed by 4919.72% to $852298.0 in 2022, then crashed by 41.34% to $500000.0 in 2023, then crashed by 69.6% to $152000.0 in 2024.
  • Its Other Non Operating Income was $152000.0 in FY2024, compared to $500000.0 in FY2023 and $852298.0 in FY2022.